Trastuzumab-DM1: a clinical update of the novel antibody-drug conjugate for HER2-overexpressing breast cancer.

Molecular medicine (Cambridge, Mass.)

Volumn 18, Issue , 2012, Pages 1473-1479

  Barginear, Myra F ^a   John, Veena ^b   Budman, Daniel R ^b  

^a DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADO-TRASTUZUMAB EMTANSINE; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MAYTANSINE; MONOCLONAL ANTIBODY; TRASTUZUMAB EMTANSINE;

ARTICLE; BREAST TUMOR; CHEMISTRY; CLINICAL TRIAL (TOPIC); FEMALE; HUMAN; METABOLISM; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; IMMUNOCONJUGATES; MAYTANSINE; RECEPTOR, ERBB-2; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 84877302244     PISSN: None     EISSN: 15283658     Source Type: None    
DOI: 10.2119/molmed.2012.00302     Document Type: Article

References (0)